Deckman - they're not merely close to solving one form of macular degeneration, the wet form, they know how to do it. In February this year, the European Commission approved a new drug, Macugen for treatment of all types of wet AMD. This, and another drug, Lucentis, are both awaiting approval from the National Institute of Clinical Excellence. NICE is reviewing Macugen in 2007 with the second appraisal meeting on 28 March 2007 and guidance not being given until August 2007. This is horrifyingly slow and it should be fast-tracked through the system.